Semaglutide
A GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes, chronic weight management, and additional labeled uses depending on brand and indication.
Also referenced as: Ozempic, Wegovy, Rybelsus
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Ozempic, Wegovy, Rybelsus
FDA label signal · 682 trials · 4361 PubMed results
What semaglutide is
Semaglutide is a GLP-1 receptor agonist used in branded prescription products including Ozempic, Wegovy, and Rybelsus. The approved indication depends on the product and label, but semaglutide is now central to both diabetes care and chronic weight-management treatment in the United States.
Why it matters
Semaglutide helped define the current GLP-1 era because it pushed appetite control and weight-loss pharmacology into the mainstream. It is also one of the clearest examples of why brand, indication, and formulation matter more than the ingredient name alone.
Regulatory context
FDA has approved semaglutide in different branded products for different uses. Relevant official FDA pages include:
That distinction matters because unapproved or compounded products are not interchangeable with labeled FDA-approved products.
Practical reading note
When people say “semaglutide,” they may be talking about:
- diabetes treatment
- chronic weight management
- off-label use
- compounded or research-market material
Those are not the same category of product or risk profile.
What to watch
If you are researching semaglutide, the important questions are usually:
- which branded or unbranded product is actually being discussed
- whether the use is on-label or off-label
- whether the product is FDA-approved, compounded, or sold outside regulated medical channels
That framing is often more useful than repeating hype-cycle language about miracle weight-loss drugs.